Compare

CJC-1295 vs Ipamorelin

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

810 users report co-tracking this pair (26% of CJC-1295 trackers also track Ipamorelin).

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CJC-1295

670 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 64% · Mixed 18% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
-59
Recovery
-110
Digestive comfort
-71
Skin appearance
1
Appetite control
-102

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
-143
Anxiety
-30
Flushing
-106
Headache
-3
GI discomfort
-103

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
8
0.2–0.4 mg
11
0.4–0.6 mg
21
0.6–1 mg
15
1–2 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing34stacking27side effects30cjc-129528

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 147 repeat reporters

Ipamorelin

530 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 44% · Mixed 46% · Unfavorable overall 10%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
41
Skin appearance
173
Appetite control
167
Energy
143
Mood
73

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
137
Headache
72
GI discomfort
132
Dizziness
139
Fatigue
72

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
6
0.2–0.4 mg
10
0.4–0.6 mg
20
0.6–1 mg
10
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing14stacking27side effects10ipamorelin13

How repeat users are trending

Among repeat reporters, 54% said they felt similar to their last entry, 30% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 117 repeat reporters

Sources (7)

Published sources linked on the CJC-1295 and Ipamorelin wiki pages.

  1. PubMed

    Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295

    Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006

    Source
    Wiki study page →
  2. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    CJC-1295 growth hormone studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    Ipamorelin, a new growth hormone-releasing peptide

    Johansen PB, Nowak J, Skjaerbaek C, et al. Eur J Endocrinol. 2001

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    Ipamorelin growth hormone studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  6. PubMed

    Ipamorelin, the first selective growth hormone secretagogue

    Raun K, Hansen BS, Johansen NL, et al. European journal of endocrinology. 1998

    Source
    Wiki study page →
  7. PubMed

    The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism

    Lu Z, Ngan MP, Liu JYH, et al. Physiology & behavior. 2024

    Source
    Wiki study page →